ORMP — Oramed Pharmaceuticals Inc

Founder-Led

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

Trend Edge Setup Score

Trend Edge rates ORMP Bullish with a Setup Score of 59, net conviction 29, actionability 122. How the Setup Score works →

Total Setup Score59
Directional BiasBullish
Net Conviction29
Actionability122 (in range)

Key signals behind this score

About Oramed Pharmaceuticals Inc

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$4.37
Market Cap$186M
Float29.9M
Shares Outstanding41.6M
P/E (TTM)1.08
Price/Sales (TTM)86.55
vs. Analyst Target+60.2% to analyst PT
Earnings Growth (YoY)493.50%
Dividend Rate0.3%
Analyst Target Price$7.00

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 $2.7M -$11.5M $2.6M -$11.3M
2021 $2.7M -$22.2M $2.7M -$25.0M
2022 $2.7M -$37.8M $2.7M -$37.0M
2023 $1.3M $5.5M $1.3M $7.3M
2024 N/A -$19.1M -$193,000 -$14.9M
2025 $2.0M $64.0M $13,000 $75.4M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Sep 2025 N/A $48.4M
Dec 2025 N/A $10.0M
Mar 2026 N/A $38.3M
Jun 2026 N/A $78.2M

Ownership & Float

Insider Ownership21.4%
Institutional Ownership45.1%
Short Float3.9%
% of All Funds Holding0.97%
Number of Funds Holding85

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$4.66Near-term / short-term trend
Weekly40-Week SMA$3.99Medium-term trend
Weekly80-Week SMA$3.16Cyclical trend (business cycle)
Weekly200-Week SMA$2.96Secular trend (multi-year)
Monthly10-Month SMA$4.10Near-term monthly trend
Monthly20-Month SMA$3.26Medium-term monthly trend
Monthly40-Month SMA$2.90Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$4.20 support 1.04x 1 months ago
$3.90 support 2.22x 3 months ago
$2.90 support 2.32x 8 months ago
$2.40 support 1.65x 10 months ago

Historical Earnings Reactions (77 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap 0.35% 0.00% 42.86% 9.09% -10.00%
1 Day 1.52% 0.15% 50.65% 19.21% -26.00%
1 Week 4.20% 0.00% 48.05% 58.16% -22.19%
2 Weeks 4.99% 1.68% 55.84% 93.50% -33.33%
1 Month 3.46% 0.29% 50.00% 135.43% -43.62%

Next earnings: November 12, 2026 (34 days away)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

MonthAvg ReturnWin RateSamples
Jan7.0%63.2%19
Feb1.9%52.6%19
Mar0.0%42.1%19
Apr4.6%78.9%19
May5.9%63.2%19
Jun-0.2%40.0%20
Jul3.0%45.0%20
Aug0.8%35.0%20
Sep-2.5%40.0%20
Oct-6.8%21.1%19
Nov8.9%47.4%19
Dec1.6%36.8%19

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday 0.38% 45.1% 918
Tuesday 0.15% 42.8% 1004
Wednesday -0.05% 41.3% 1003
Thursday 0.04% 40.9% 984
Friday 0.27% 42.7% 979

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 45.1%

Insider Transactions — Smart Summary

Total insider ownership: 21.4%

Founder-led management: Nadav Kidron (President, CEO & Executive Chairman), Miriam Kidron (Chief Scientific Officer & Director)

12-Month Insider Activity Summary

Total Filings4
Net Value-$983,204.56
Net Shares Change-210,360
% of Float-0.7%
C-Suite Filings4
Clusters Detected0

Key Insiders

NameTitleNet ValueFilingsActivity
Hexter Joshua COO & CBO -$562,261 2 N/A
Gabay Avraham Chief Financial Officer -$420,943.56 2 N/A

Significant Filings

DateInsiderTitleNet ValuePrice After
2026-10-02 Hexter Joshua COO & CBO -$135,330 Transaction at $4.51, now -3.1%
2026-10-02 Gabay Avraham Chief Financial Officer -$90,200 Transaction at $4.51, now -3.1%
2026-07-02 Hexter Joshua COO & CBO -$426,931 Transaction at $4.08, now +7.2%
2026-07-02 Gabay Avraham Chief Financial Officer -$330,743.56 Transaction at $4.51, now -3.1%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Oramed Pharmaceuticals Inc (ORMP) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for ORMP on Trend Edge →